Atrium Therapeutics reported second quarter 2026 financial results on August 13, 2026. The company earned a $15 million milestone payment from Bristol Myers Squibb under their global cardiovascular collaboration and recognized $3.0 million in collaboration revenue primarily related to R&D services. For the quarter ended June 30, 2026, research and development expenses were $15.3 million and general and administrative expenses were $10.3 million, resulting in a net loss of approximately $20.2 million. As of June 30, 2026, the company held $263.9 million in cash, cash equivalents, and short-term investments, which management believes is sufficient to fund operations through mid-2028. The filing also highlighted FDA clearance for the IND application for ATR 1072 and the launch of the Corventis Phase 1/2 trial in PRKAG2 syndrome. Atrium Therapeutics operates as a biopharmaceutical company developing RNA therapeutics targeted to the heart.

Atrium Therapeutics, Inc. announced on July 14, 2026, that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for ATR 1072, allowing the company to proceed with its Corventis™ Phase 1/2 clinical trial for treating Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (PRKAG2) syndrome. Atrium Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for genetic disorders.